Codex DNA to Present at the Jefferies London Healthcare Conference
November 11 2021 - 8:03AM
Codex DNA, Inc. (Nasdaq: DNAY), a pioneer in automated benchtop
synthetic biology systems, today announced that Todd R. Nelson,
PhD, the company’s chief executive officer, will present virtually
at the 12th Annual Jefferies London Healthcare Conference. The
pre-recorded presentation will be available on Thursday, November
18 at 5:00 pm Greenwich Mean Time / 12:00 pm Eastern time / 9:00 am
Pacific time.
The presentation can be accessed through a link on the investors
section of Codex DNA’s website at https://ir.codexdna.com. An
archived replay of the webcast will be available for 30 days
following the event.
About Codex DNACodex DNA is
empowering scientists with the ability to create novel, synthetic
biology-enabled solutions for many of humanity’s greatest
challenges. As inventors of the industry-standard Gibson Assembly®
method and the first commercial automated benchtop DNA and mRNA
synthesis system, Codex DNA is enabling rapid, accurate, and
reproducible writing of DNA and mRNA for numerous downstream
markets. The company’s award-winning BioXp™ system consolidates,
automates, and optimizes the entire synthesis, cloning, and
amplification workflow. As a result, it delivers virtually
error-free synthesis of DNA/RNA at scale within days and hours
instead of weeks or months. Scientists around the world are using
the technology in their own laboratories to accelerate the
design-build-test paradigm for novel, high-value products for
precision medicine, biologics drug discovery, vaccine and
therapeutic development, genome editing, and cell and gene therapy.
Codex DNA is a public company based in San Diego. For more
information, visit codexdna.com.
Forward-Looking StatementsThis press release
contains forward-looking statements. All statements other than
statements of historical facts contained herein are forward-looking
statements reflecting the current beliefs and expectations of
management made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These statements
include statements regarding scaling our operations and growing our
customer base, progress made on achieving our corporate goals, the
future release of products and services, the contribution that Eton
Bioscience will make to our business and the overall strength of
our business. Such statements are based on current assumptions that
involve risks and uncertainties that could cause actual outcomes
and results to differ materially. These risks and uncertainties,
many of which are beyond our control, include risks described in
the section entitled Risk Factors and elsewhere in our Quarterly
Report on Form 10-Q filing made with the Securities and Exchange
Commission on November 10, 2021. These forward-looking statements
speak only as of the date hereof and should not be unduly relied
upon. Codex DNA disclaims any obligation to update these
forward-looking statements.
Contact:Richard LepkeDirector of Investor
Relations(619) 840-5392RichardL@codexdna.com
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Jul 2024 to Aug 2024
Codex DNA (NASDAQ:DNAY)
Historical Stock Chart
From Aug 2023 to Aug 2024